Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.
|Articles|November 7, 2011
Twitter feed Psychiatric Times Coverage of HMP Global, LLC’s Psych Congress® Conference 2011
Listen
0:00 / 0:00
Key Takeaways
- Presentations delivered at Psych Congress® served as the source material for the page’s articles and interviews.
- Psychiatric Times maintains editorial independence and is neither affiliated with nor endorsed or sponsored by any third-party organizations.
Advertisement
The articles and interviews featured on this page were developed by Psychiatric Times editorial staff and contributors based on presentations delivered at Psych Congress®, an annual conference produced by HMP Global, LLC. Psychiatric Times is an independent publication and is not affiliated with, endorsed by, or sponsored by HMP Global, LLC. All content on this page reflects the independent editorial judgment of Psychiatric Times and does not represent the views, positions, or communications of HMP Global, LLC.
Advertisement
Related to this article
Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.
Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
FDA Shelves Fast-Track Drug Review Initiative
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1
5